Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: Randomized, single-center trial at 10 years

American Journal of Transplantation

Volumn 12, Issue 12, 2012, Pages 3363-3376

  Ciancio, G ^a   Sageshima, J ^a   Chen, L ^a   Gaynor, J J ^a   Hanson, L ^a   Tueros, L ^a   Velarde, E Montenora ^a   Gomez, C ^a   Kupin, W ^a   Guerra, G ^a   Mattiazzi, A ^a   Fornoni, A ^a   Pugliese, A ^a   Roth, D ^a   Wolf, M ^a   Burke, G W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

End stage renal disease; mycophenolate mofetil; rapamycin; simultaneous kidney pancreas transplant; tacrolimus; type 1 diabetes

Indexed keywords

CORTICOSTEROID; CREATININE; DACLIZUMAB; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; LIPID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PARESIS; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; PROGNOSIS; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84870500235     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04235.x     Document Type: Article

References (30)

1. Burke GW, Ciancio G, Sollinger HW,. Advances in pancreas transplantation. Transplantation 2004; 77 (Suppl 9): S62-S67.
2. Sollinger HW, Odorico JS, Becker YT, et al,. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg 2009; 250: 618-630.
3. Burke GW 3rd, Kaufman DB, Millis JM, et al,. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: Three-year results. Transplantation 2004; 77: 1269-1275.
4. Kaufman DB, Burke, GW 3rd, Bruce DS, et al,. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003; 3: 855-864.
5. Salazar A, McAlister VC, Kiberd BA, Bitter-Suermann H, Al-Kerithy MF, MacDonald AS,. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: Effect on renal function. Transplant Proc 2001; 33: 1038-1039.
6. Burke GW, Ciancio G, Figueiro J, et al,. Can acute rejection be prevented in SPK transplantation? Transplant Proc 2002; 34: 1913-1914.
7. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S,. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303-309.
8. Gallon L, Perico N, Dimitrov BD, et al,. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006; 6: 1617-1623.
9. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B,. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273-2280.
10. Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB,. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: Tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007; 83: 1324-1329.
11. Kaplan B, Kirk AD,. Tacrolimus and sirolimus: When bad things happen to good drugs. Am J Transplant 2006; 6: 1501-1502.
12. Heilman RL, Mazur MJ, Reddy KS,. Immunosuppression in simultaneous pancreas-kidney transplantation. Progress to date. Drugs 2010; 70: 793-804.
13. Budde K, Becker T, Ams W, et al,. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomized, controlled trial. Lancet 2011; 377: 837-847.
14. Ciancio G, Gaynor JJ, Sageshima J, et al,. Favorable outcomes with machine perfusion and longer pump times in kidney transplantation: A single-center, observational study. Transplantation, 2010; 90: 882-890.
15. Sageshima J, Ciancio G, Gaynor JJ, et al,. Addition of anti-CD25 to thymoglobulin for induction therapy: Delayed return of peripheral blood CD25-positive population. Clin Transplant 2011; 25: E132-E135.
16. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
17. Vendrame F, Pileggi A, Laughlin E, et al,. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010; 59: 947-957.
18. Tekemoto SK, Pinsky BW, Schnitzler MA, et al,. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007; 7: 2704-2711.
19. Matas AJ, Gillingham KJ, Payne WD, Najarian JS,. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857-859.
20. Drachenberg CB, Papadimitriou JC, Farney A, et al,. Pancreas transplantation: The histologic morphology of graft loss and clinical correlation. Transplantation 2001; 71: 1784-1791.
21. Axelrod D, Leventhal JR, Gallon LG, Parker MA, Kaufman DB,. Reduction of CMV disease with steroid-free immunosuppression in simultaneous pancreas-kidney transplant recipients. Am J Transplant 2005; 5: 1423-1429.
22. Lipshutz GS, Mahanty H, Feng S, et al,. BKV in simultaneous pancreas-kidney transplant recipients: A leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant 2005; 5: 366-73.
23. Kaufman, DB, Leventhal JR, Gallon LG, Parker, MA,. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-long-term results. Am J Transplant 2006; 6: 331-339.
24. Bustami RT, Ojo AO, Wolfe RA, et al,. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93.
25. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
26. Amer H, Cosio FG,. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2490-2492.
27. Cravedi P, Ruggenenti P, Remuzzi G,. Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet 2009; 373: 1235-1236.
28. Ciancio G, Burke GW, Gaynor JJ, et al,. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845-852.
29. Cortazar F, Molnar MZ, Czira ME, et al,. Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant 2012; 12: 379-387.
30. Nathan DM, Cleary PA, Backlund JY, et al,. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 2005; 353: 2643-2653.